Adaptimmune Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	25.95	91.14	143.99	108.03	149.95
Short-Term Investments	-	60.47	2.95	96.57	219.63
Cash & Short-Term Investments	25.95	151.61	146.94	204.61	369.58
Cash Growth	-82.88%	3.18%	-28.18%	-44.64%	0.37%
Accounts Receivable	6.99	1.45	0.82	7.44	0.75
Other Receivables	3.48	14.53	46.1	30.65	33.26
Receivables	10.47	15.98	46.92	38.09	34.01
Inventory	-	7.38	1.33	1.28	0.75
Prepaid Expenses	-	10.03	9.95	9.47	9.04
Other Current Assets	8.89	3.17	2.41	1.93	2.08
Total Current Assets	45.31	188.17	207.55	255.37	415.46
Property, Plant & Equipment	16.29	51.22	71.71	71.54	51.37
Other Intangible Assets	0.02	3.88	0.33	0.44	1
Other Long-Term Assets	1.73	2.7	3.03	1.57	1.72
Total Assets	63.36	245.96	282.62	328.92	469.55
Accounts Payable	16.61	8.69	8.13	4.75	8.11
Accrued Expenses	-	30.9	28.85	29.06	29.58
Current Portion of Leases	4.93	4.71	5.38	2.73	2.32
Current Income Taxes Payable	-	-	1.4	-	-
Current Unearned Revenue	-	12.3	28.97	23.52	22.2
Other Current Liabilities	0.7	7.93	0.05	4.44	0.33
Total Current Liabilities	22.24	64.53	72.79	64.5	62.54
Long-Term Debt	-	50.24	-	-	-
Long-Term Leases	9.15	19.26	19.85	20.35	23.15
Long-Term Unearned Revenue	-	95.82	149.06	160.89	177.22
Other Long-Term Liabilities	-	4.27	1.4	1.3	0.67
Total Liabilities	31.39	234.11	243.1	247.04	263.59
Common Stock	2.16	2.09	1.87	1.4	1.34
Additional Paid-In Capital	829.99	1,106	1,065	990.66	959.61
Retained Earnings	-914.45	-1,094	-1,023	-909.3	-743.85
Comprehensive Income & Other	114.28	-1.9	-3.75	-0.88	-11.14
Shareholders' Equity	31.97	11.85	39.51	81.88	205.96
Total Liabilities & Equity	63.36	245.96	282.62	328.92	469.55
Total Debt	14.08	74.21	25.24	23.08	25.47
Net Cash (Debt)	11.87	77.4	121.7	181.53	344.11
Net Cash Growth	-84.67%	-36.41%	-32.96%	-47.25%	-0.11%
Net Cash Per Share	0.04	0.31	0.61	1.13	2.21
Filing Date Shares Outstanding	262.83	257.23	246.83	165.31	156.73
Total Common Shares Outstanding	262.83	255.94	227.17	164.52	156.26
Working Capital	23.08	123.64	134.76	190.87	352.92
Book Value Per Share	0.12	0.05	0.17	0.50	1.32
Tangible Book Value	31.95	7.97	39.18	81.44	204.96
Tangible Book Value Per Share	0.12	0.03	0.17	0.49	1.31
Machinery	-	39.91	38.97	34.92	32.65
Construction In Progress	-	0.28	0.05	28.73	5.4
Leasehold Improvements	-	43.01	57.94	28.46	28.7